Sulfadiazine
 |
 |
| Systematic (IUPAC) name |
| 4-amino-N-pyrimidin- 2-yl-benzenesulfonamide |
| Clinical data |
| AHFS/Drugs.com |
monograph |
| MedlinePlus |
a682130 |
| Pregnancy cat. |
? |
| Legal status |
Approved Drug |
| Routes |
Cream |
| Pharmacokinetic data |
| Bioavailability |
? |
| Metabolism |
? |
| Half-life |
? |
| Excretion |
? |
| Identifiers |
| CAS number |
68-35-9  Y |
| ATC code |
J01EC02 QJ01EQ10 |
| PubChem |
CID 5215 |
| DrugBank |
DB00359 |
| ChemSpider |
5026  N |
| UNII |
0N7609K889 N |
| KEGG |
D00587 Y |
| ChEMBL |
CHEMBL439 N |
| Chemical data |
| Formula |
C10H10N4O2S |
| Mol. mass |
250.278 g/mol |
 N (what is this?) (verify)
|
Sulfadiazine is a sulfonamide antibiotic.
|
Contents
- 1 Uses
- 2 Side effects
- 3 Brand names
- 4 See also
- 5 External links
|
Uses
It eliminates bacteria that cause infections by stopping the production of folic acid inside the bacterial cell, and is commonly used to treat urinary tract infections (UTIs).
In combination, sulfadiazine and pyrimethamine, can be used to treat toxoplasmosis, a disease caused by Toxoplasma gondii.
Side effects
Side effects reported for sulfadiazine include: nausea, upset stomach, loss of appetite, and dizziness.
Brand names
Lantrisul; Neotrizine; Sulfa-Triple #2; Sulfadiazine; Sulfaloid; Sulfonamides Duplex; Sulfose; Terfonyl; Triple Sulfa; Triple Sulfas; Triple Sulfoid
See also
External links
- Sulfadiazine (patient information)
|
Antibacterials: nucleic acid inhibitors (J01E, J01M)
|
|
Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis) |
| DHFR inhibitor |
- 2,4-Diaminopyrimidine
- Trimethoprim#
- Brodimoprim
- Tetroxoprim
- Iclaprim†
|
|
Sulfonamides
(DHPS inhibitor) |
Short-
acting |
- Sulfaisodimidine
- Sulfamethizole
- Sulfadimidine
- Sulfapyridine
- Sulfafurazole
- Sulfanilamide
- Sulfathiazole
- Sulfathiourea
|
|
Intermediate-
acting |
- Sulfamethoxazole
- Sulfadiazine#
- Sulfamoxole
|
|
Long-
acting |
- Sulfadimethoxine
- Sulfadoxine
- Sulfalene
- Sulfametomidine
- Sulfametoxydiazine
- Sulfamethoxypyridazine
- Sulfaperin
- Sulfamerazine
- Sulfaphenazole
- Sulfamazone
|
|
|
| Other/ungrouped |
- sulfanilamide
- Sulfacetamide
- Sulfametrole
|
|
| Combinations |
- Trimethoprim/sulfamethoxazole#
|
|
|
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication) |
| 1st g. |
- Cinoxacin‡
- Flumequine
- Nalidixic acid
- Oxolinic acid
- Pipemidic acid
- Piromidic acid
- Rosoxacin
|
|
Fluoro-
quinolones |
| 2nd g. |
- Ciprofloxacin#
- Enoxacin‡
- Fleroxacin‡
- Lomefloxacin
- Nadifloxacin
- Ofloxacin
- Norfloxacin
- Pefloxacin
- Rufloxacin
|
|
| 3rd g. |
- Balofloxacin
- Grepafloxacin‡
- Levofloxacin
- Pazufloxacin
- Sparfloxacin‡
- Temafloxacin‡
- Tosufloxacin
|
|
| 4th g. |
- Besifloxacin
- Clinafloxacin†
- Garenoxacin
- Gemifloxacin
- Moxifloxacin
- Gatifloxacin‡
- Sitafloxacin
- Trovafloxacin‡/Alatrofloxacin‡
- Prulifloxacin
|
|
| Vet. |
- Danofloxacin
- Difloxacin
- Enrofloxacin
- Ibafloxacin
- Marbofloxacin
- Orbifloxacin
- Pradofloxacin
- Sarafloxacin
|
|
| Related (DG) |
- Aminocoumarins: Novobiocin
|
|
|
|
Anaerobic DNA
inhibitors |
| Nitro- imidazole derivatives |
- Metronidazole#
- Tinidazole
- Ornidazole
|
|
| Nitrofuran derivatives |
- Nitrofurantoin#
- Furazolidone‡
- Nifurtoinol
|
|
|
| RNA synthesis |
Rifamycins/
RNA polymerase |
- Rifampicin#
- Rifabutin
- Rifapentine
- Rifaximin
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
gr+f/gr+a(t)/gr-p(c)/gr-o
|
|
|
|
|
|
Antiparasitics – antiprotozoal agents – Chromalveolate antiparasitics (P01)
|
|
Alveo-
late |
|
Apicom-
plexa
|
|
Conoidasida/
(Coccidiostats)
|
|
Cryptosporidiosis
|
thiazole (nitazoxanide)
|
|
|
Isosporiasis
|
trimethoprim/sulfamethoxazole#
|
|
|
Toxoplasmosis
|
pyrimethamine • sulfadiazine
|
|
|
|
Aconoidasida
|
|
Malaria
|
|
Individual
agents
|
|
Hemozoin
inhibitors
|
|
aminoquinolines
|
(4-): amodiaquine# • chloroquine#
(8-): primaquine# • pamaquine
|
|
|
4-methanolquinolines
|
mefloquine#• quinine# • quinidine
|
|
|
Other
|
lumefantrine (combined with artemether)
halofantrine
|
|
|
|
Antifolates
|
|
DHFR inhibitors
(antifols)
|
pyrimethamine
proguanil# • chlorproguanil (biguanides)
|
|
|
Sulfonamides
|
sulfadoxine • sulfamethoxypyrazine
|
|
|
Coformulation
|
Fansidar# (sulfadoxine/pyrimethamine, known as SP)
|
|
|
|
Sesquiterpene
lactones
|
artemether# • artesunate#• dihydroartemisinin •
arteether/artemotil • artemisinin
|
|
|
Other
|
atovaquone (with proguanil as as Malarone)
tetracycline • doxycycline#
clindamycin
pyronaridine
piperaquine
|
|
|
|
Combi-
nations
|
|
Fixed-dose (coformulated) ACTs
|
artemether-lumefantrine#
artesunate-amodiaquine (ASAQ)
artesunate-mefloquine (ASMQ)
dihydroartemisinin-piperaquine
artesunate-pyronaridine
|
|
|
Other combinations
(not co-formulated)
|
artesunate/SP • artesunate/mefloquine •
quinine/tetracycline • quinine/doxycycline • quinine/clindamycin
|
|
|
|
|
Babesiosis
|
clindamycin
|
|
|
|
|
Cilio-
phora
|
Balantidiasis: Tetracycline
|
|
|
Hetero-
kont |
Blastocystosis: Metronidazole
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
(what is this?) (verify)